Haemonetics Corporation (HAE) Financials

The erratic revenue trajectory suggests that the company's reliance on plasma collection volumes may be subject to significant timing issues or external market pressures. Investors should monitor whether the recent return to positive growth in 2026Q4 represents a durable recovery or merely a temporary rebound from previous quarterly contractions.

The stability of gross margins near the mid-50% range suggests that the company's proprietary disposables and software-integrated ecosystem provide a meaningful buffer against inflationary pressures. However, the slight variance in margins across the last ten quarters warrants investigation into whether product mix shifts toward lower-margin hospital offerings are beginning to offset the benefits of the core plasma business.

The inability to consistently expand operating margins despite revenue growth suggests that the company is currently in an investment phase, likely tied to the integration of recent acquisitions or increased commercial spending. Analysts should scrutinize whether these elevated operating expenses are temporary integration costs or a structural shift in the company's cost-to-serve model.